Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
基本信息
- 批准号:10589801
- 负责人:
- 金额:$ 11.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AdherenceAsthmaCellsChildhoodClinicalCommunicable DiseasesCommunicationComplementDataDevelopmentDissectionEnsureEpigenetic ProcessFundingGeographyGoalsHumanImmuneImmune responseImmunologyIn VitroInfantInfrastructureIntellectual PropertyInternationalLeadershipLifeMediatingMolecularOutcomePRTN3 genePredispositionProcessProductivityProgress ReportsProperty RightsProteomicsRecommendationResearch PersonnelResearch Project GrantsShapesStructureSystems BiologyTechnologyTeleconferencesUnited States National Institutes of HealthVaccinesWorkconflict resolutiondata managementdesignimprovedin silicointer-institutionalmaterial transfer agreementmeetingsprogramsrespiratorysymposiumsynergismtimelinetranscriptomicsvaccine responsevaccinology
项目摘要
PROJECT SUMMARY: IDEAL Administrative Core
Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes
that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious
disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow
complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3)
research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the
study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed
studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute
streamlined processes which facilitate productive interactions among investigators from each IDEAL Project
and Core. We will achieve this goal by pursuing the following Specific Aims (SAs):
SA1. Provide infrastructure for administrative leadership aimed at building an interactive and
collaborative working team resulting in maximal project synergy.
SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads
by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as
seminars/symposia focused on the IDEAL project.
SA3. Manage and optimize communication within our IDEAL team and between our team, the
other NIH supported IDEAL teams and the IDEAL Steering Committee.
SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by
implementing recommendations of the Conflicts Resolution Group (CRG).
SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress
reports sent to the NIH.
SA6. Protect intellectual property rights of our investigators and execute material transfer
agreements.
SA7. Implement the data management/sharing plan among investigators within and outside of our
IDEAL team.
Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to
project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.
项目概要:IDEAL行政核心
我们的总体建议将调查免疫发育的早期生活(理想),以确定理想的内涵型
这与儿童期的关键临床结果相对应,包括疫苗反应,呼吸道感染,
疾病和哮喘。我们将通过以下三个不同但综合的研究来实现这一目标
通过计算机模拟(项目1,PR 1)、表观遗传学(PR 2)和体外(PR 3)的尖端互补方法
研究项目。鉴于拟议工作的科学范围、复杂性和地理范围,
研究IDEAL行政核心(AC)将是至关重要的,以优化拟议的质量和影响,
研究,并确保及时提供预计的交付成果。IDEAL-AC的目标是
简化流程,促进每个IDEAL项目的调查人员之间的有效互动
和核心。我们将通过以下具体目标实现这一目标:
SA 1.为行政领导提供基础设施,
协作的工作团队,最大限度地发挥项目的协同作用。
SA 2.促进项目和核心领导之间的沟通和互动
通过定期举行电话会议/面对面会议、年度会议以及
以IDEAL项目为重点的研讨会/专题讨论会。
SA 3.管理和优化IDEAL团队内部以及我们的团队、
其他NIH支持IDEAL团队和IDEAL指导委员会。
SA 4.解决IDEAL项目内外可能出现的潜在冲突,
执行冲突解决小组的建议。
SA 5.提供财政、监管和科学监督,审查和巩固年度进展
将报告发送给NIH。
SA6.保护我们研究人员的知识产权并执行材料转移
协定
SA7。在我们内部和外部的研究者之间实施数据管理/共享计划
理想的团队
总体而言,IDEAL AC将确保NIH资金的适当管理,并保持遵守
项目时间表,所有这些都是为了优化和扩大拟议研究的科学影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OFER LEVY其他文献
OFER LEVY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OFER LEVY', 18)}}的其他基金
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10435035 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10589826 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10435043 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
- 批准号:
10589800 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
- 批准号:
10435036 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10290547 - 财政年份:2021
- 资助金额:
$ 11.18万 - 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
- 批准号:
10205742 - 财政年份:2021
- 资助金额:
$ 11.18万 - 项目类别:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
新生儿队列发现和验证新生儿疫苗免疫原性的生物标志物
- 批准号:
10323182 - 财政年份:2020
- 资助金额:
$ 11.18万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10221106 - 财政年份:2020
- 资助金额:
$ 11.18万 - 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
- 批准号:
10265669 - 财政年份:2020
- 资助金额:
$ 11.18万 - 项目类别:
相似海外基金
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
- 批准号:
10664599 - 财政年份:2023
- 资助金额:
$ 11.18万 - 项目类别:
MICA: Interrogating the functional impact of novel asthma genetic variants using genomics and inducible pluripotent stem cell-derived epithelial cells
MICA:利用基因组学和诱导多能干细胞衍生的上皮细胞探讨新型哮喘遗传变异的功能影响
- 批准号:
MR/X000974/1 - 财政年份:2023
- 资助金额:
$ 11.18万 - 项目类别:
Fellowship
Mucosal Associated Invariant T cells in the Obese-asthma endotype
肥胖哮喘内型中的粘膜相关不变 T 细胞
- 批准号:
10607523 - 财政年份:2023
- 资助金额:
$ 11.18万 - 项目类别:
Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
- 批准号:
10563192 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Defining the development of tissue-resident memory Th2 cells in allergic asthma
定义过敏性哮喘中组织驻留记忆 Th2 细胞的发育
- 批准号:
10501568 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Break Down Barriers: Respiratory epithelial cells as modulators of dendritic cells during the pathogen associated allergic sensitization and acute asthma exacerbation
打破障碍:在病原体相关的过敏致敏和哮喘急性发作期间,呼吸道上皮细胞作为树突状细胞的调节剂
- 批准号:
504226880 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Research Grants
CD4+T Cells, Alarmins and Human Airway Smooth Muscle Function in Asthma
CD4 T 细胞、警报素和哮喘患者气道平滑肌功能
- 批准号:
461568 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Operating Grants
Defining the development of tissue-resident memory Th2 cells in allergic asthma
定义过敏性哮喘中组织驻留记忆 Th2 细胞的发育
- 批准号:
10670871 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Transcriptional Responses to Wildfire Pollution in Airway Epithelial Cells Identify Genetic Risk Factors and Mechanisms of Asthma Exacerbations
气道上皮细胞对野火污染的转录反应确定了哮喘恶化的遗传风险因素和机制
- 批准号:
10573003 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别:
Allergen-specific lung-resident Tregs in asthma: Targetable suppressors of resident memory Th2 cells
哮喘中过敏原特异性肺常驻 Tregs:常驻记忆 Th2 细胞的靶向抑制因子
- 批准号:
10418189 - 财政年份:2022
- 资助金额:
$ 11.18万 - 项目类别: